胃癌腹膜转移的诊断和相关治疗

doi:10.16139/j.1007-9610.2021.01.006

摘要/Abstract

中图分类号:

R735.2

张景辉, 徐袁, 印慨. 胃癌腹膜转移的诊断和相关治疗[J]. 外科理论与实践, 2021, 26(01): 28-33.

ZHANG Jinghui, XU Yuan, YIN Kai. Diagnosis with associated treatment of peritoneal metastatic gastric cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 28-33.

参考文献 46

[1]	Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors[J]. Int J Cancer, 2014, 134(3):622-628. doi: 10.1002/ijc.28373 pmid: 23832847
[2]	Montori G, Coccolini F, Ceresoli M, et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art[J]. Int J Surg Oncol, 2014, 2014:912418.
[3]	Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition[J]. Gastric Cancer, 2011, 14(2):101-112.
[4]	Hasegawa H, Fujitani K, Nakazuru S, et al. Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom/tumor marker-based versus CT-based[J]. Anticancer Res, 2014, 34(9):5169-5174. pmid: 25202110
[5]	Arslan H, Fatih Ozbay M, Calli I, et al. Contribution of diffusion weighted MRI to diagnosis and staging in gastric tumors and comparison with multi-detector computed tomography[J]. Radiol Oncol, 2017, 51(1):23-29. doi: 10.1515/raon-2017-0002 pmid: 28265229
[6]	Ytre-Hauge S, Dybvik JA, Lundervold A, et al. Preoperative tumor texture analysis on MRI predicts high-risk di-sease and reduced survival in endometrial cancer[J]. J Magn Reson Imaging, 2018, 48(6):1637-1647. doi: 10.1002/jmri.26184 pmid: 30102441
[7]	Kim HY, Kim YH, Yun G, et al. Could texture features from preoperative CT image be used for predicting occult peritoneal carcinomatosis in patients with advanced gastric cancer?[J]. PLoS One, 2018, 13(3):e0194755.
[8]	Benson AB 3rd, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014[J]. J Natl Compr Canc Netw, 2014, 12(7):1028-1059.
[9]	Li Z, Li Z, Jia S, et al. Depth of tumor invasion and tumor-occupied portions of stomach are predictive factors of intra-abdominal metastasis[J]. Chin J Cancer Res, 2017, 29(2):109-117.
[10]	Emoto S, Ishigami H, Yamashita H, et al. Clinical signifi-cance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination[J]. Gastric Cancer, 2012, 15(2):154-161.
[11]	Takata A, Kurokawa Y, Fujiwara Y, et al. Prognostic va-lue of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer[J]. World J Surg, 2014, 38(5):1107-1111.
[12]	Satoh Y, Mori K, Kitano K, et al. Analysis for the combination expression of CK20, FABP1 and MUC2 is sensitive for the prediction of peritoneal recurrence in gastric cancer[J]. Jpn J Clin Oncol, 2012, 42(2):148-152.
[13]	Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma[J]. Ann Surg, 2009, 250(2):242-246.
[14]	Lemoine L, Sugarbaker P, van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma[J]. Int J Hyperthermia, 2017, 33(5):582-592.
[15]	Ito S, Ohashi Y, Sasako M. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial[J]. BMC Cancer, 2018, 18(1):449.
[16]	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4)[J]. Gastric Cancer, 2017, 20(1):1-19.
[17]	Shirao K, Boku N, Yamada Y, et al. Randomized phase Ⅲ study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)[J]. Jpn J Clin Oncol, 2013, 43(10):972-980.
[18]	Nakayama I, Chin K, Matsushima T, et al. Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis[J]. Int J Clin Oncol, 2017, 22(6):1060-1068. doi: 10.1007/s10147-017-1164-4 pmid: 28748355
[19]	Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis[J]. Gastric Cancer, 2017, 20(Suppl 1):111-121. doi: 10.1007/s10120-016-0662-9 pmid: 27803990
[20]	van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer[J]. Lancet, 2016, 388(10060):2654-2664. doi: S0140-6736(16)30354-3 pmid: 27156933
[21]	Wilke H, Muro K, van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11):1224-1235.
[22]	Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance[J]. Int J Clin Oncol, 2015, 20(2):273-281.
[23]	Kelly RJ. Immunotherapy for esophageal and gastric cancer[J]. Am Soc Clin Oncol Educ Book, 2017, 37:292-300.
[24]	Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2016, 17(6):717-726. doi: S1470-2045(16)00175-3 pmid: 27157491
[25]	Ni X, Wu P, Wu J, et al. Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites[J]. Oncol Lett, 2017; 14(2):1691-1696.
[26]	Rau B, Brandl A, Piso P, et al. Peritoneal metastasis in gastric cancer: results from the German database[J]. Gastric Cancer, 2020, 23(1):11-22.
[27]	Li Y, Zhou YF, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies[J]. World J Gastroenterol, 2016, 22(30):6906-6916.
[28]	Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 2011, 18(6):1575-1581.
[29]	Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis[J]. J Clin Oncol, 2019, 37(23):2028-2040.
[30]	Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases[J]. Int J Hyperthermia, 2017, 33(5):562-570.
[31]	Chan DY, Syn NL, Yap R, et al. Conversion surgery post-intraperitoneal paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. Are we ready?[J]. J Gastrointest Surg, 2017, 21(3):425-433.
[32]	Imano M, Peng YF, Itoh T, et al. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis[J]. Anticancer Res, 2012, 32(9):4071-4075.
[33]	Yamaguchi H, Kitayama J, Ishigami H, et al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis[J]. Cancer, 2013, 119(18):3354-3358. doi: 10.1002/cncr.28204 pmid: 23798046
[34]	Ishigami H, Fujiwara Y, Fukushima R, et al. Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial[J]. J Clin Oncol, 2018, 36(19):1922-1929.
[35]	Alyami M, Hubner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377.
[36]	Giger-Pabst U, Demtroder C, Falkenstein TA, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma[J]. BMC Cancer, 2018, 18(1):442. doi: 10.1186/s12885-018-4363-0 pmid: 29669524
[37]	Alyami M, Bonnot PE, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for nonresectable peritoneal metastasis from gastric cancer[J]. Eur J Surg Oncol, 2019, 45:592.
[38]	Wu P, Wang P, Ma B, et al. Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis[J]. Cancer Manag Res, 2018, 10:4759-4771.
[39]	朱正纲. 晚期胃癌转化治疗的理念与临床意义[J]. 外科理论与实践, 2017, 22(1):1-4.
[40]	Okabe H, Ueda S, Obama K, et al. Induction chemothe-rapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination[J]. Ann Surg Oncol, 2009, 16(12):3227-3236.
[41]	Ramos M, Pereira MA, Charruf AZ, et al. Conversion therapy for gastric cancer: expanding the treatment possibilities[J]. Arq Bras Cir Dig, 2019, 32(2):e1435.
[42]	Koemans WJ, van der Kaaij RT, Boot H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE Ⅱ)[J]. BMC Cancer, 2019, 19(1):420. doi: 10.1186/s12885-019-5640-2 pmid: 31060544
[43]	Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage Ⅳ gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2):329-338.
[44]	Ishigami H, Yamaguchi H, Yamashita H, et al. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings[J]. Gastric Cancer, 2017, 20(Suppl 1):128-134.
[45]	Cho H, Ryu MH, Kim KP, et al. Phase Ⅰ/Ⅱ study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis[J]. Gastric Cancer, 2017, 20(6):970-977.
[46]	Fushida S, Kinoshita J, Yagi Y, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study[J]. Oncol Rep, 2008, 19(5):1305-1310. pmid: 18425392

胃癌腹膜转移的诊断和相关治疗

Diagnosis with associated treatment of peritoneal metastatic gastric cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 46

相关文章 15

编辑推荐

Metrics

本文评价

[1]	严超, 陆晟, 燕敏, 朱正纲. 《日本胃癌治疗指南2021（第6版）》解读及瑞金实践[J]. 外科理论与实践, 2023, 28(04): 326-354.
[2]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[3]	孙强, 姚骏, 张鑫, 杜杉珊, 王伟军. 近端胃切除抗反流消化道重建方式的研究进展[J]. 外科理论与实践, 2023, 28(04): 388-393.
[4]	胡文庆, 杨垠浩, 崔鹏, 魏伟. 食管胃结合部腺癌腹腔镜经腹-左膈肌路径近端胃加食管下段切除高位消化道重建现状[J]. 外科理论与实践, 2023, 28(03): 226-232.
[5]	燕速, 郑民华. 中国单孔及减孔腹腔镜胃癌手术实践[J]. 外科理论与实践, 2023, 28(03): 233-239.
[6]	颜凌, 王凌云, 陈勇, 杜联军. 双能CT图像深度学习重建算法在胃癌术前T分期中的应用[J]. 诊断学理论与实践, 2023, 22(02): 154-159.
[7]	王远江, 邹浩. 胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[8]	范清泉, 宋晓玲, 顾钧. 外泌体在胃癌中的研究展望[J]. 外科理论与实践, 2023, 28(02): 177-180.
[9]	徐凯, 李百文. 早期胃癌及胃癌前病变的内镜黏膜下剥离术治疗[J]. 内科理论与实践, 2023, 18(02): 102-106.
[10]	朱正纲. 胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(01): 1-6.
[11]	赵法之, 赵平. 胃癌治疗手术中心论体系的形成与完善[J]. 外科理论与实践, 2023, 28(01): 24-30.
[12]	李国立, 郭飞龙. 动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35.
[13]	刘文韬, 刘福坤. 中国胃癌围术期综合治疗概述与展望[J]. 外科理论与实践, 2023, 28(01): 36-41.
[14]	张欢, 陈勇. 影像组学在胃癌诊断中的新进展[J]. 外科理论与实践, 2023, 28(01): 42-48.
[15]	邓仕杰, 袁菲. EB病毒阳性的胃癌与伴有淋巴样间质的胃癌——诊断及分子检测进展[J]. 外科理论与实践, 2023, 28(01): 53-57.